×
About 711,245 results

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
https://doi.org/10.1002/art.41752
Arthritis & Rheumatology (Hoboken, N.J.); Fraenkel L, Bathon JM et. al.

Jun 9th, 2021 - To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising c...

Fluconazole - fluconazole tablet-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d11e0926-cd15-49ba-b0ee-2b6d4e009dd8

Dec 30th, 2022 - Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, di...

Then and now: A ‘lifetime’ of advancement in upper GI
https://www.mdedge.com/gihepnews/article/255934/upper-gi-tract/then-and-now-lifetime-advancement-upper-gi
David A. Katzka, MD, MDedge News

Jul 1st, 2022 - Fifteen years is a lifetime for the advancement of medical research. This seems particularly true for upper GI tract disorders.

Certolizumab pegol for maintenance of medically induced remission in Crohn's disease.
https://doi.org/10.1002/14651858.CD013747.pub2
The Cochrane Database of Systematic Reviews; Okabayashi S, Yamazaki H et. al.

Jul 1st, 2022 - Crohn's disease (CD) is a disease with an impaired immune response characterized by chronic, relapsing-remitting, and progressive inflammation mainly affecting the gastrointestinal tract. Certolizumab pegol (CZP) is a biological agent that regulates the impaired immune response by controlling tumour necrosis factor-α (TNFα). However, the efficacy and safety of long-term administration of CZP fo...

A Phase IIb Randomized Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonar...
https://doi.org/10.1164/rccm.202112-2824OC
American Journal of Respiratory and Critical Care Medicine; Raghu G, Mouded M et. al.

Jul 1st, 2022 - Treatment options for idiopathic pulmonary fibrosis (IPF) are limited. To evaluate the efficacy and safety of BG00011, an anti-αvβ6 IgG1 monoclonal antibody, in the treatment of patients with IPF. In a phase IIb randomized, double-blind, placebo-controlled trial, patients with IPF (forced vital capacity [FVC] ≥50% predicted, on or off background therapy) were randomized 1:1 to once-weekly subcu...

Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Cons...
https://doi.org/10.1093/labmed/lmac055
Laboratory Medicine; Ipe TS, Ugwumba B et. al.

Jul 1st, 2022 - Many therapies are used to treat COVID-19, the disease caused by the virus SARS-CoV-2, including convalescent plasma. The clinical utility of using 2 units of convalescent plasma for COVID-19 hospitalized patients is not fully understood. Many therapies are used to treat COVID-19, the disease caused by the virus SARS-CoV-2, including convalescent plasma. The clinical utility of using 2 units of...

Feasibility of Preoperative Dose-Painting Intensity Modulated Radiation Therapy (IMRT) ...
https://doi.org/10.1245/s10434-022-12053-7 10.1016/j.ejca.2013.11.021 10.1016/j.ijrobp.2011.04.009 10.1245/ASO.2006.05.035 10.1002/cncr.22005 10.1097/SLA.0000000000001063 10.1016/S1470-2045(20)30446-0 10.1016/S1470-2045(20)30632-X 10.1200/JCO.2021.39.15_suppl.11566 10.1200/JCO.2012.44.3747 10.1002/jso.26586 10.1200/JCO.2008.18.0802 10.1002/jso.24256 10.1097/00000658-199809000-00008 10.1200/JCO.2021.39.15_suppl.11550
Annals of Surgical Oncology; Zhang M, Crago A et. al.

Jul 1st, 2022 - The role of radiation therapy (RT) in resectable retroperitoneal sarcoma (RPS) remains controversial; however, preoperative RT may play an important role in borderline-resectable (at risk of R2 resection) disease. We evaluated the outcome of such patients treated with preoperative dose-painting IMRT followed by planned resection. Between January 2001 and December 2017, 30 patients with borderli...

What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day M...
https://doi.org/10.1007/s11523-022-00897-8 10.1016/S0140-6736(21)00135-5 10.1056/NEJMra1011442 10.1016/S1470-2045(14)70442-5 10.3322/caac.21660 10.1001/jama.2022.0003 10.1016/j.mayocp.2012.06.014 10.1177/095952874402700129 10.1056/NEJMoa2024850 10.1097/PPO.0000000000000523 10.1097/HS9.0000000000000163 10.1002/ajh.25791 10.3390/cancers13061285 10.3390/cancers13194787 10.1038/s41408-021-00550-z 10.1007/s11523-020-00758-2 10.1177/2040620721989585 10.3390/cancers12123576 10.1016/j.ejca.2016.10.018 10.1016/j.annonc.2020.11.014 10.1016/S0140-6736(19)31240-1 10.18632/oncotarget.27973 10.2217/14796694.2.5.577 10.1016/s0190-9622(96)90122-x 10.1038/sj.leu.2403852 10.1038/nrc1323 10.1016/s0022-3476(64)80626-0 10.1177/2040620711413165 10.1016/s0029-7844(01)01662-3 10.1002/bdrc.21096 10.1002/cpt196563292 10.1002/cpt196563298 10.1002/cpt196563303 10.1517/14656566.1.4.849 10.1097/00124743-200002000-00003 10.1046/j.1440-0960.2002.00608.x 10.1093/toxsci/kfr088 10.1016/s0149-2918(03)80085-1 10.1517/13543784.7.12.2043 10.1073/pnas.91.9.4082 10.1038/nm0195-27 10.1111/j.1365-2141.1994.tb08304.x 10.3109/10428199509054750 10.1177/1078155220975825 10.1177/2042098612452291 10.1053/j.seminoncol.2016.10.008 10.1111/imr.12233 10.1053/ctrv.2000.0188 10.1016/j.ejca.2006.02.017 10.3389/fonc.2020.625199 10.1182/blood-2004-07-2909 10.1007/s002770000236 10.3343/alm.2015.35.6.563 10.1038/sj.bmt.1704555 10.1182/blood-2002-08-2441 10.1006/exer.1997.0292 10.1186/1471-2121-7-17 10.1111/j.1476-5381.2009.00446.x 10.1200/JCO.2005.03.723 10.3390/jcm9061765 10.3390/ijms19072031 10.1038/sj.leu.2403285 10.1182/blood.v99.12.4525 10.3390/ijms17091506 10.1038/leu.2009.236 10.3389/fimmu.2021.632399 10.1084/jem.187.11.1885 10.1182/blood-2003-02-0361 10.1182/blood.v98.1.210 10.1023/a:1026548226770 10.1007/s12185-016-2073-4 10.1126/science.1177319 10.1182/blood-2011-05-356063 10.3389/fcell.2021.629326 10.1038/s41598-020-57512-x 10.1155/2017/9130608 10.3390/ph13050095 10.1016/j.biopha.2020.110114 10.1126/science.1249543 10.1097/PPO.0000000000000354 10.1038/nature14610 10.1038/s41589-020-0645-3 10.1182/blood-2007-10-078022 10.1111/ejh.13003 10.1038/sj.leu.2403728 10.1016/s0140-6736(83)90739-0 10.1182/blood.V67.5.1298.1298 10.1182/blood.V70.3.869.869 10.1056/NEJM199607113350204 10.1056/NEJMoa032290 10.1182/blood.V92.9.3131 10.1056/NEJM198405243102104 10.1200/JCO.1989.7.10.1514 10.1186/2162-3619-1-27 10.1056/NEJM199911183412102 10.1182/blood.v98.2.492 10.1023/a:1011132808904 10.1182/blood.v98.13.3846 10.1038/sj.thj.6200175 10.1182/blood-2002-09-2846 10.1016/S0953-6205(03)91244-1 10.1046/j.1365-2141.2003.04473.x 10.1200/JCO.2003.01.055 10.1111/j.1365-2141.2004.04879.x 10.4065/79.7.875 10.1038/sj.thj.6200401 10.1038/sj.leu.2403322 10.1038/sj.thj.6200326 10.1038/sj.thj.6200403 10.1038/sj.leu.2403890 10.1007/s00277-005-1007-7 10.1200/JCO.2005.14.381 10.1111/j.1365-2141.2005.05521.x 10.1158/1078-0432.CCR-05-0213 10.4065/81.7.889 10.3816/CLM.2006.n.028 10.1182/blood-2006-08-042275 10.1634/theoncologist.12-1-99 10.1111/j.1600-0609.2007.00908.x 10.1111/j.1600-0609.2007.00930.x 10.1111/j.1349-7006.2008.00792.x 10.1111/j.1365-2141.2008.07360.x 10.1038/leu.2008.99 10.1038/leu.2008.235 10.1111/j.1365-2141.2008.07076.x 10.1111/j.1600-0609.2008.01131.x 10.1007/s00277-009-0856-x 10.1038/leu.2010.58 10.1007/s00277-010-0943-z 10.1007/s00277-011-1276-2 10.1007/s00277-011-1217-0 10.1007/s00277-011-1320-2 10.1111/j.1600-0609.2011.01729.x 10.3324/haematol.2011.044271 10.1111/j.1600-0609.2012.01775.x 10.1200/JCO.2011.37.4918 10.3109/10428194.2012.664844 10.1002/ajh.23822 10.1111/bjh.13435 10.1111/bjh.14263 10.1016/S2352-3026(16)30165-X 10.1002/cam4.970 10.1007/s00280-017-3310-0 10.1111/bjh.15645 10.1038/s41416-019-0581-8 10.1002/ajh.25633 10.1111/bjh.17504 10.1182/blood-2010-10-299487 10.1111/j.1365-2141.2005.05914.x 10.1182/blood.V96.9.2943 10.1111/j.1600-0609.2008.01121.x 10.5045/br.2020.S008 10.20471/acc.2018.57.03.18 10.1002/ajh.24181 10.1111/bjh.14481 10.1038/s41408-019-0219-3 10.1182/blood.v98.5.1614 10.1111/bjh.12325 10.1182/blood.V122.21.5377.5377 10.1182/blood.V124.21.3459.3459 10.1111/bjh.17248 10.1002/ajh.24954 10.1111/j.1365-2141.2007.06921.x 10.1159/000365534 10.2147/CMAR.S105163 10.1111/bjh.13296 10.1001/jamaoncol.2017.4519 10.1182/blood-2020-139092 10.1016/j.critrevonc.2017.02.007 10.1345/aph.1A155 10.1038/sj.leu.2405062 10.1111/j.1365-2141.2010.08416.x 10.1016/j.mayocp.2017.01.003 10.3904/kjim.2013.28.3.263 10.1200/JCO.2005.03.0221 10.1200/EDBK_238527 10.1038/leu.2015.80 10.1182/blood-2016-01-693580 10.1111/bjh.12946 10.1111/j.1365-2141.2008.06982.x 10.3324/haematol.2018.205476 10.1590/1413-812320182410.28522017 10.1007/s00277-016-2660-8 10.1182/blood-2011-11-374249 10.1097/SPC.0b013e328349dc17 10.1182/blood-2006-05-022962 10.1038/s41408-020-0273-x 10.1182/blood-2011-06-357038 10.1200/JCO.2009.25.6081 10.1080/10428194.2019.1683736 10.1182/blood-2011-03-341669 10.3389/fmed.2021.612696 10.1056/NEJMoa1402551 10.1182/blood-2014-12-613927 10.1182/blood-2015-11-679415 10.1080/14656566.2016.1236915 10.1016/j.hkjn.2013.09.001 10.3390/cancers13205036 10.1016/j.kint.2020.11.010 10.18632/oncotarget.26270 10.2215/CJN.06100616 10.1182/blood-2007-10-117457 10.1177/0091270007309563 10.1111/j.1600-0609.2004.00272.x 10.3324/haematol.10759 10.1016/j.bbmt.2010.02.020 10.1182/blood-2011-05-353995 10.1111/j.1365-2141.2011.08754.x 10.1038/leu.2012.182 10.3324/haematol.2015.133629 10.1182/blood-2019-128157 10.1182/blood-2011-11-395749 10.1007/s12185-008-0055-x 10.1056/NEJMoa1607751 10.3389/fmolb.2021.788440 10.1111/bjh.17805 10.1186/s40364-021-00344-2 10.1016/S0140-6736(21)00933-8 10.1016/j.annonc.2021.12.003 10.1016/S1470-2045(19)30788-0 10.1177/2040620720979813 10.1182/blood-2020-139332 10.1155/2012/621958 10.1158/1535-7163.MCT-18-1146 10.1158/1078-0432.CCR-17-0344 10.1038/s41408-021-00469-5 10.1182/bloodadvances.2020002524 10.1158/2643-3230.BCD-21-0073 10.1126/scitranslmed.abb6295 10.1001/jamanetworkopen.2021.16357 10.1001/jamanetworkopen.2021.3497
Targeted Oncology; Costa BA, Mouhieddine TH et. al.

Jul 1st, 2022 - Immunomodulatory drugs (IMiDs) have become an integral part of therapy for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM). IMiDs bind to cereblon, leading to the degradation of proteins involved in B-cell survival and proliferation. Thalidomide, a first-generation IMiD, has little to no myelosuppressive potential, negligible renal clearance, and long-proven anti-myeloma ac...

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adu...
https://doi.org/10.1007/s12325-022-02206-1 10.1038/s41586-020-2622-0 10.1038/nrd4278 10.1038/s41591-021-01330-9 10.1038/s41586-020-2639-4 10.1038/s41586-020-2814-7 10.1056/NEJMoa2027906 10.1182/blood-2006-04-015024 10.1016/j.ymthe.2018.12.011 10.1038/mt.2008.200 10.1038/s41586-021-03275-y 10.1038/s41586-021-03653-6 10.1056/NEJMoa2034577 10.1056/NEJMoa2110345 10.1016/S1473-3099(21)00681-2 10.1056/NEJMc2032195 10.1056/NEJMc2103916 10.3390/vaccines10030359 10.1056/NEJMoa2114583 10.1016/j.lanepe.2021.100208 10.1038/s41586-020-03041-6 10.1056/NEJMc2113468 10.1016/S0140-6736(21)01420-3
Advances in Therapy; Li J, Hui AM et. al.

Jul 1st, 2022 - BNT162b1 is a lipid nanoparticle-formulated, nucleoside-modified mRNA SARS-CoV-2 vaccine. Here, we report safety and immune persistence data following a primary two-dose vaccination schedule administered 21 days apart. Immune persistence was determined at month 3 in 72 younger participants (aged 18-55 years) and at month 6 in 70 younger and 69 older participants (aged 65-85 years). In younger p...

Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Syste...
https://doi.org/10.1007/s12325-022-02195-1 10.1053/j.seminoncol.2016.11.004 10.1186/s13045-019-0807-5 10.1634/theoncologist.2020-0141 10.3389/fonc.2019.01513 10.1002/cam4.3391 10.1038/bcj.2014.55 10.1016/j.bbmt.2014.12.013 10.1136/bmj.b2700 10.1371/journal.pmed.1000097 10.1136/bmj.i4919 10.1186/1471-2288-11-41 10.1037/1082-989X.11.2.193 10.1097/MD.0000000000015987 10.1038/leu.2017.211 10.1186/s40164-018-0110-0 10.1038/s41408-018-0106-3 10.1016/j.clml.2019.09.597 10.1038/s41375-019-0384-1 10.1007/s00277-019-03815-7 10.1016/S0140-6736(19)31240-1 10.4067/S0034-98872019001201561 10.1016/j.clml.2019.09.362 10.1182/blood.2019000241 10.1016/j.clml.2019.09.341 10.1007/s10147-019-01436-8 10.1159/000495338 10.1016/S2352-3026(20)30099-5 10.3747/co.27.5385 10.1182/blood.2020007522 10.1111/ejh.13349 10.1007/s12185-019-02764-1 10.1016/S2352-3026(20)30323-9 10.1182/blood.2020005288 10.1371/journal.pmed.1003454 10.1111/j.1365-2141.2008.06997.x 10.1200/JCO.2008.19.5370 10.1007/s00277-009-0726-6 10.1038/leu.2009.26 10.1111/j.1365-2141.2009.07981.x 10.1016/S0140-6736(10)61424-9 10.1182/blood-2010-02-271676 10.1177/147323001103900544 10.1182/blood-2011-05-355081 10.1182/blood-2012-02-408922 10.1200/JCO.2011.39.6820 10.1200/JCO.2011.39.5137 10.3324/haematol.2013.100396 10.1111/bjh.13004 10.1200/JCO.2013.54.8164 10.1111/bjh.13582 10.3324/haematol.2015.124347 10.1182/blood.V126.23.5380.5380 10.1182/blood.V126.23.27.27 10.1182/blood.V128.22.674.674 10.1182/blood-2016-01-693580 10.1056/NEJMoa1611750 10.1038/bmt.2016.214 10.1016/j.bbmt.2016.11.011 10.1111/bjh.14920 10.1002/hon.2439_151 10.1182/blood-2017-07-796607 10.1200/JCO.19.02515 10.1038/sj.bmt.1703382 10.1038/s41408-019-0205-9 10.1016/j.clml.2019.09.002 10.3109/10428194.2012.728597 10.1016/S1470-2045(20)30452-6 10.1016/S1470-2045(21)00535-0
Advances in Therapy; Yang G, Geng C et. al.

Jul 1st, 2022 - The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has become standard of care for transplant-eligible patients with newly diagnosed MM (NDMM). This study aimed to determine the efficacy of RVd as induction therapy in terms of response rates and survival outcomes of transplant-eligible patients with NDMM. The databases of Medline, Embase, and Cochrane Library were searched unt...

Advances in stem cell therapy for intestinal diseases: mechanisms, perspectives regardi...
https://doi.org/10.2174/1574888X17666220629094253
Current Stem Cell Research & Therapy; Fan W, Chang L et. al.

Jul 1st, 2022 - Intestinal disease is a common disease, which can cause serious digestion and absorption disorders, endanger the lives of patients and seriously affect the quality of life of people. Finding an effective treatment is a difficult problem at present, and stem cell therapy as a treatment has high application potential in intestinal-related diseases. This paper mainly summarizes the mechanism, rese...

Advances of Exosomal microRNAs and Proteins in Ovarian Cancer Diagnosis, Prognosis, and...
https://doi.org/10.2174/1566524022666220628160009
Current Molecular Medicine; Qin T, Chen F et. al.

Jul 1st, 2022 - Late diagnosis, postoperative recurrence, and chemotherapy resistance are the main causes of the high mortality rate of ovarian cancer (OC). Understanding the molecular mechanisms in the pathogenesis and progression of OC may contribute to discovering new tumor biomarkers and therapeutic targets for OC. Exosomes are small extracellular vesicles derived from different types of cells that carry c...

A case of Fingolimod-associated Cryptococcal Meningitis.
https://doi.org/10.2174/1570162X20666220629124225
Current HIV Research; Darazam IA, Rabiei MM et. al.

Jul 1st, 2022 - Leukopenia, a rare adverse effect of Fingolimod therapy, paves the way for opportunistic infections. In this study, we reported a rare fingolimod associated cryptococcal meningitis. A 39-year-old woman with RRMS was referred to the emergency department. The patient's major complaints were headache, fever, weakness, and progressive loss of consciousness within the last two days prior to the refe...

High Dose Rate Brachytherapy in non - melanoma skin cancer - systematic review.
https://doi.org/10.1111/dth.15675
Dermatologic Therapy; Krzysztofiak T, Kamińska-Winciorek G et. al.

Jul 1st, 2022 - Non-melanoma skin cancers (NMSC's) are the most common malignancies worldwide. Millions of new cases every year present challenge to healthcare systems. Recent years brought numerous new data concerning High Dose Rate (HDR) brachytherapy as treatment option for NMSC's. International guidelines do not recognize brachytherapy as a method of choice given lack of randomized trials, however many pro...

Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular car...
https://doi.org/10.1007/s00432-022-04057-3 10.1016/j.ejca.2020.06.007 10.1056/NEJMoa1613683 10.1056/NEJMoa1507643 10.1056/NEJMoa1200694 10.1172/jci80011 10.3322/caac.21338 10.1200/JCO.2016.72.1316 10.1038/s41598-018-28337-6 10.1158/2326-6066.Cir-16-0237 10.1016/s0140-6736(17)31046-2 10.1136/gutjnl-2019-320116 10.1002/cncr.32339 10.1200/jco.20.00808 10.1056/NEJMoa1915745 10.1200/jco.19.01307 10.1084/jem.192.7.1027 10.1136/bmj.d5928 10.1056/NEJMoa1003466 10.1016/s0140-6736(17)31827-5 10.1056/NEJMcibr2106594 10.1200/jco.20.03555 10.1159/000451016 10.1016/s1470-2045(20)30156-x 10.5582/bst.2018.01311 10.1016/j.ccell.2019.08.007 10.1371/journal.pmed.1000097 10.1056/NEJMoa1510665 10.1016/s1470-2045(20)30011-5 10.1080/2162402x.2018.1548243 10.1007/s12072-020-10064-8 10.1016/s2468-1253(17)30181-4 10.1016/S1470-2045(21)00252-7 10.1056/NEJMp1510079 10.1080/13543784.2021.1972969 10.1080/17474124.2021.1973431 10.1056/NEJMoa1412082 10.3322/caac.21262 10.1016/j.hbpd.2019.09.007 10.1016/s1470-2045(19)30167-6 10.1158/1078-0432.Ccr-18-2484 10.1001/jamaoncol.2020.4564 10.1016/s1470-2045(18)30351-6
Journal of Cancer Research and Clinical Oncology; Wen W, Zhang Y et. al.

Jul 1st, 2022 - Programmed death ligand 1(PD-L1)/programmed cell death-1(PD-1) inhibitors have shown promising efficacy in unresectable patients with advanced hepatocellular carcinoma (HCC), but the results are not consistent. Our goal was to evaluate the safety and efficacy of PD-L1/PD-1 inhibitors or plus anti-CTLA-4 antibody or anti-VEGF agents for the treatment of unresectable HCC. Cochrane library, Embase...

Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: ...
https://doi.org/10.1111/dth.15672
Dermatologic Therapy; Shirzad Moghadam F, Kianfar N et. al.

Jul 1st, 2022 - The ongoing COVID-19 pandemic has raised concerns regarding the outcome of this infection in patients with autoimmune bullous dermatoses (AIBDs) due to effect of drugs used to treat these disorders. This investigation was performed from the onset of the pandemic to June 1, 2021. Patients with AIBDs who contracted COVID-19 were evaluated. A generalized linear model was employed to find the predi...

Understanding anti-TNF treatment failure: Does serum triiodothyronine-to-thyroxine (T3/...
https://doi.org/10.1111/apt.17089
Alimentary Pharmacology & Therapeutics; Lin S, Chanchlani N et. al.

Jul 1st, 2022 - During illness, adaptations of the hypothalamic-pituitary-thyroid axis reduce energy expenditure, protein catabolism and modulate immune responses to promote survival. Lower serum free triiodothyronine-to-thyroxine (fT3/fT4) ratio has been linked to non-response to treatment in a range of diseases, including in biologic-treated patients with inflammatory bowel disease. To assess whether baselin...

The Comprehensive Analysis of Interferon-Related Prognostic Signature with regard to Im...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236773
Disease Markers; An Y, Duan H

Jul 1st, 2022 - Interferon plays an important role in immune response of ovarian cancer. However, the expression pattern of interferon in ovarian cancer remains unclear. This study is aimed at exploring the expression profile of interferon-relate genes and constructing an interferon-based prognostic signature in ovarian cancer. The ovarian cancer samples collected from TCGA database were viewed as the training...

Review article: Novel biomarkers in hepatitis B infection.
https://doi.org/10.1111/apt.17105
Alimentary Pharmacology & Therapeutics; Lok J, Dusheiko G et. al.

Jul 1st, 2022 - Chronic hepatitis B remains a global health problem with an estimated 296 million people affected worldwide. Individuals are at risk of serious complications such as cirrhosis and hepatocellular carcinoma and accurately predicting these clinical endpoints has proven difficult. However, several viral biomarkers have recently been developed, including quantitative HBV surface antigen (qHBsAg), he...

Lymphocytic myocarditis presenting as acute myocardial infarction: a case report and re...
https://doi.org/10.1177/03000605221108933
The Journal of International Medical Research; Huang Z, Feng G et. al.

Jul 1st, 2022 - We report a case that presented as acute myocardial infarction (AMI) caused by lymphocytic myocarditis (LM), and explore the relationship between AMI and LM. We also performed a literature search to identify publications that previously reported LM-associated myocardial infarction. Coronary angiography of our patient revealed normal coronary arteries. However, a perfusion-metabolism mismatch in...